July 2024 Briefs

A phase 1 trial of COM503 in metastatic or advanced solid tumors is expected to begin in Q4 2024.

Findings from the phase 3 PERSEUS study support the approval of subcutaneous daratumumab and bortezomib, lenalidomide, and dexamethasone in this patient population.

The investigational new drug application for UB-VV111, potentially the first in situ generated CD19 CAR T-cell therapy, has been cleared by the FDA, and a phase 1 trial in hematologic malignancies will begin.

Avutometinib plus defactinib shows promising early results in pancreatic cancer, earning an orphan drug designation from the FDA.

VCN-01 has been granted rare pediatric disease designation by the FDA for the treatment of retinoblastoma, a rare eye cancer.